Anti-PD-L1 Treatment Induced Central Diabetes Insipidus.

ABSTRACT:

Context

Immune checkpoint inhibitors, including anti-programmed cell death protein 1 (PD-1), anti-programmed cell death protein ligand 1 (PD-L1), and anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) monoclonal antibodies, have been widely used in cancer treatment. They are known to cause immune-related adverse events (irAEs), which resemble autoimmune diseases. Anterior pituitary hypophysitis with secondary hypopituitarism is a frequently reported irAE, especially in patients receiving anti-CTLA4 treatment. In contrast, posterior pituitary involvement, such as central diabetes insipidus (DI), is relatively rare and is unreported in patients undergoing PD-1/PD-L1 blockade.

Case description

We describe a case of a 73-year-old man with Merkel cell carcinoma who received the a

SUBMITTER: Zhao C 

PROVIDER: S-EPMC5800826 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature